ESTRO meets Asia 2024 - Abstract Book

S162

Interdisciplinary – Head & neck

ESTRO meets Asia 2024

Conclusion:

By integrating longitudinal treatment response measurements, we constructed and extensively validated RAIRI, providing real-time updated quantitative risk estimates for individuals, significantly superior to conventional risk models. Beyond the prognostic model, RAIRI could be a predictive biomarker facilitating personalized AC selection.

Keywords: longitudinal biomarker, treatment response

58

Proffered Paper

Survival and Loss of Lifetime for Nasopharyngeal Carcinoma Patients with Progression-Free 24 Months Yang Liu, Junlin Yi

Radiation oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China